Octagon Capital Advisors’s Mirati Therapeutics, Inc. Common Stock MRTX Stock Holding History

Octagon Capital Advisors’s Portfolio MRTX Stock Details MRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-655,051	Closed	-$28.5M	–	51
2023 Q3	$28.5M	Sell	655,051 -94,949	-13%	-$3.39M	4.38%	8
2023 Q2	$27.1M	Hold	750,000	–	–	3.77%	6
2023 Q1	$27.9M	Hold	750,000	–	–	4.01%	8
2022 Q4	$34M	Buy	750,000 +529,000	+239%	+$34.2M	5.29%	5
2022 Q3	$15.4M	Buy	+221,000	New	+$16.4M	2.66%	9

Other funds holding MRTX

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Simplicity Solutions Minneapolis, Minnesota $3.66B AUM 23.51% 1-Year Est. Return

Braslyn New Providence, Bahamas $7.81M AUM 338.68% 1-Year Est. Return

Octagon Capital Advisors's MRTX Position: Q4 2023 in Review

Octagon Capital Advisors sold out of Mirati Therapeutics, Inc. Common Stock (MRTX) in Q4 2023, closing a stake of 655,051 shares — an estimated $28.5M sold.

Octagon Capital Advisors first reported a position in MRTX in Q3 2022 and held it in 5 quarters. The position peaked at $34M in Q4 2022. 217 funds tracked by Wall St. Rank hold MRTX as of Q4 2023.

Octagon Capital Advisors reported no remaining Mirati Therapeutics, Inc. Common Stock position as of Q4 2023 after selling out during the quarter.
Octagon Capital Advisors sold 655,051 Mirati Therapeutics, Inc. Common Stock shares in Q4 2023, an estimated $28.5M.
Octagon Capital Advisors first reported a position in Mirati Therapeutics, Inc. Common Stock in Q3 2022 and held it in 5 quarters.
Octagon Capital Advisors's Mirati Therapeutics, Inc. Common Stock position peaked at $34M in Q4 2022.
217 funds tracked by Wall St. Rank held Mirati Therapeutics, Inc. Common Stock as of Q4 2023.

Based on Octagon Capital Advisors's 13F filing for Q4 2023, filed 14 Feb 2024.